Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001094

Drug Information
NameNatalizumab    
SynonymsNatalizumab (INN); Natalizumab; Tysabri; D06886; 189261-10-7; Tysabri (TN)    
Trade NameTysabri; Antegren    
IndicationMultiple sclerosisApproved    [1]
Therapeutic ClassImmunomodulatory Agents    
CAS NumberCAS 189261-10-7
PubChem Substance IDSID 49661786.    
TargetIntegrin alpha-4Antibody[2][3]
Ref 1Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. To Reference
Ref 2Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J Neurol. 2009 Jul 16. [Epub ahead of print] To Reference
Ref 3Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 Feb 3;72(5):402-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543